Table 3.
Peptides synthesized for in vitro analysis.a
| Peptidea | Sequence | KDb | Selection target (comment) |
|---|---|---|---|
| D4-Btn | DYCNLSVSWCYP-K (Btn) | ND | U-CLL mAb 068 (this work; family 2) |
| D4-3K | DYCNLSVSWCYP-GSGKKK | NB | |
| D2-Btn | VSCNPFSWLPRCYA-K (Btn) | ND | U-CLL mAb 068 (this work; family 5) |
| D2-3K | VSCNPFSWLPRCYA-GSGKKK | 58 μmol/L | |
| E6-Btn | FPCWALPSQYLCRP-K (Btn) | ND | U-CLL mAb 068 (this work) |
| E6-3K | FPCWALPSQYLCRP-GSGKKK | 111 μmol/L | |
| PhD-068-4-Btn | WPLWSIPPFSPR-K (Btn) | weak | U-CLL mAb 068 (reference [5]) |
| PhD-068-4-3K | WPLWSIPPFSPR-KKKK | weak | |
| PhD-169-8-Btn | DNYAAALAQRAR-K (Btn) | ND | M-CLL mAb 169 (reference [5]) |
| PhD-169-8-4K | DNYAAALAQRAR-KKKK | 31 nmol/L |
a
All peptides synthesized as C-terminal amides.
b
ND, not determined; NB, no binding.